“With generative AI becoming more capable of producing remarkably convincing radiology reports, there’s a greater risk of fabricated reports being used to falsify medical histories and support fraudulent claims,” the team cautioned.
When working-age adults develop cardiovascular disease, it often ends up eating up a significant amount of their income. Are insurance companies doing enough to help these patients?
Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.